Table 1 Characteristics of studies included in the meta-analysis

Agostoni et al. (2001)

Italy

Hyperphenylalaninemia

F/M

one 500 mg capsule LCPUFA/4 Kg body weight

12

20

10

parallel

LDL, TG, HDL, TC.

Ahmadi et al. (2014)

Iran

Metabolic Syndrome

F/M

omega-3 tablets(2.4 gr/day)

2

53

14

parallel

LDL, TG, HDL, TC.

Ald´ amiz et al. (2006)

Spain

Methylmalonic acidemia

F/M

25 mg/kg per day DHA

3

60

10

crossover

TG, HDL, TC.

Ateya et al. (2017) [17]

Egypt

Hemodialysis

F/M

1-g oral omega-3 capsule

4

49

14.7

parallel

LDL, TG, HDL, TC.

Boyraz et al. (2015) [26]

Turkey

NAFLD

F/M

1000 mg dose of PUFA

12

108

13.8

parallel

LDL, TG, HDL, TC.

de Ferranti et al. (2014) [14]

USA

Hypertriglyceridemia

F/M

1 g capsule ( 840 mg omega-3 FA, 465 mg EPA and 375 mg DHA, in 4 mg of carrier vegetable oil)

6

21

14.5

parallel

LDL, TG, HDL, TC.

Del-Río-Navarro et al. (2019) [16]

Mexico

Obese

F/M

3 g/day of omega-3

3

130

13

parallel

TG, HDL, TC.

Gidding et al. (2014) [15]

USA

Hypertriglyceridemia

F/M

4 g of fish oil

2

42

14

crossover

LDL, TG, HDL, TC.

Harel et al. (2002)

USA

Migraine

F/M

2 capsules (1-g n-3/day each)

2

27

15

crossover

TG.

Huang et al. (2019)

Mexico

Hypertriglyceridemia

F/M

3 g/day of 3 PUFAs supplementation

3

65

12.6

parallel

TG, HDL, TC.

Janczyk et al. (2015)

Poland

NAFLD

F/M

450-1300 w3 mg/day

6

64

13.1

parallel

LDL, TG, HDL, TC.

Nobili et al. (250mg) (2013)

Italy

NAFLD

F/M

250 mg DHA/d

24

40

12

parallel

TG.

Nobili et al. (500mg) (2013)

Italy

NAFLD

F/M

500 mg DHA/d

24

40

12

parallel

TG.

Pacifico (2015)

Italy

NAFLD

F/M

250 mg DHA/day

6

51

10.9

parallel

TG, HDL, TC.

Pedersen (2010)

Denmark

Metabolic Syndrome

M

1.5 g of n-3/d

4

78

14

parallel

LDL, TG, HDL, TC.